Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

European Group Offers Guidance on Managing Juvenile Dermatomyositis

Reuters Staff  |  August 30, 2016

NEW YORK (Reuters Health)—A European working group has formulated consensus-based recommendations for the diagnosis and treatment of juvenile dermatomyositis (JDM) with the goal of producing a “standard of care” for patients with JDM throughout Europe. The group is part of a European initiative called SHARE [Single Hub and Access point for pediatric Rheumatology in Europe]…

Adalimumab Lowers Risk of Uveitic Flare

Will Boggs, MD  |  August 30, 2016

NEW YORK (Reuters Health)—Adalimumab reduces the risk of uveitic flare after corticosteroid withdrawal in patients with inactive, noninfectious uveitis, according to results from VISUAL II. “Tumor-necrosis factor (TNF) inhibition, which has been demonstrated to have strong efficacy in rheumatologic disorders, can also have significant role in the management of noninfectious uveitis, even amidst the challenges…

Clazakizumab for Adults with Active PsA

Arthritis & Rheumatology  |  August 30, 2016

This is the first clinical trial of an IL-6–targeted therapy in PsA. Clazakizumab may be an effective treatment option for musculoskeletal aspects of PsA, but because of the lack of a dose response in this study, further studies are required to confirm the appropriate dose. The safety profile is consistent with the pharmacology of IL-6 blockade and prior clinical experience with this antibody in rheumatoid arthritis…

More U.S. Counties May See Obamacare Marketplace Monopoly

Trevor Hunnicutt  |  August 29, 2016

NEW YORK (Reuters)—Nearly a third of U.S. counties will likely be served by only one insurer that participates in an Affordable Care Act (ACA) marketplace in 2017, according to an analysis published Aug. 28 by the Kaiser Family Foundation. The 31% of U.S. counties that will have just a single option of insurers within the…

Exercise Therapy May Take the ‘Tired’ Out of Chronic Fatigue Syndrome

Lara C. Pullen, PhD  |  August 29, 2016

A recent review has expanded the current thinking about the benefits of exercise therapy for patients with chronic fatigue syndrome. Study participants experienced improved sleep, physical function and self-perceived general health…

No Time Theft Here: One Practice’s Success Story

Karen Appold  |  August 26, 2016

Practitioners at Orthopaedics and Rheumatology of the North Shore, in Skokie, Ill., have implemented practices for hiring and personnel management that help prevent employee time theft. Communication is open, employees are invested in the practice, and managers work to ensure employees are listened to and have clear guidelines to work by…

New York City Hospitals Settle Medicaid Repayment after Fraud Charges

Jonathan Stempel  |  August 24, 2016

NEW YORK (Reuters)—Three hospitals in New York’s Mount Sinai Health System will pay $2.95 million to settle Medicaid fraud charges for taking two years to repay more than $844,000 of improper billings that had been flagged by a whistleblower, authorities say on Wednesday. The accord resolves claims that Mount Sinai Beth Israel, Mount Sinai St….

Placebo Outperforms Glucosamine/Chondroitin Sulfate for Knee OA

Erin Blakemore  |  August 24, 2016

(Reuters Health)—Glucosamine sulfate and chondroitin sulfate are not more beneficial than placebo treatments for patients with knee osteoarthritis, a recent trial suggests. In a double-blind study, researchers investigated the efficacy of a medicine that delivered both glucosamine and chondroitin sulfate. The 164 participants all had osteoarthritis and moderate to severe knee pain. Half the participants…

FDA Approves Updated Labeling on Risk of Osteonecrosis of the Jaw for Denosumab

Michele B. Kaufman, PharmD, BCGP  |  August 24, 2016

Denosumab’s labeling now says a patient’s risk of developing osteonecrosis of the jaw may increase with prolonged exposure…

Can Anything Contain Drug Costs in the U.S.?

Lisa Rapaport  |  August 23, 2016

(Reuters Health)—The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand name medicines and changing coverage requirements for government health plans, some doctors argue. Although brand-name drugs account for only 10% of all dispensed prescriptions in the U.S., they make up 72% of drug spending,…

  • « Previous Page
  • 1
  • …
  • 482
  • 483
  • 484
  • 485
  • 486
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences